Literature DB >> 17085050

ErbB receptors: new insights on mechanisms and biology.

Bryan Linggi1, Graham Carpenter.   

Abstract

The ErbB family of four receptor tyrosine kinases occupies a central role in a wide variety of biological processes from neuronal development to breast cancer. New information continues to expand their biologic significance and to unravel the molecular mechanisms that underlie the signaling capacity of these receptors. Here, we review several aspects of ErbB receptor physiology for which new and significant information is available. These include ligand-dependent receptor dimerization and kinase activation, which is a prerequisite for all subsequent growth factor-dependent cell responses. We also address novel roles of receptor fragments in signaling, trafficking to intracellular sites, such as the nucleus, and ErbB roles in non-cancer disease processes, including schizophrenia, chronic renal disease, hypertension, and the cellular entry of infectious pathogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085050     DOI: 10.1016/j.tcb.2006.10.008

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  163 in total

1.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

Review 2.  Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.

Authors:  Edwin Li; Kalina Hristova
Journal:  Cell Adh Migr       Date:  2010-04-23       Impact factor: 3.405

Review 3.  Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.

Authors:  Nikolas Balanis; Cathleen R Carlin
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

Review 4.  Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.

Authors:  Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink
Journal:  Nitric Oxide       Date:  2014-08-19       Impact factor: 4.427

5.  Postsynaptic chromatin is under neural control at the neuromuscular junction.

Authors:  Aymeric Ravel-Chapuis; Marie Vandromme; Jean-Luc Thomas; Laurent Schaeffer
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

Review 6.  Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.

Authors:  Robert J Coffey; Mary Kay Washington; Christopher L Corless; Michael C Heinrich
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

7.  ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms.

Authors:  Daria Krivosheya; Lucia Tapia; Joshua N Levinson; Kun Huang; Yunhee Kang; Rochelle Hines; Annie K Ting; Ann Marie Craig; Lin Mei; Shernaz X Bamji; Alaa El-Husseini
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

8.  Members of the Entamoeba histolytica transmembrane kinase family play non-redundant roles in growth and phagocytosis.

Authors:  Sarah N Buss; Shinjiro Hamano; Alda Vidrich; Clive Evans; Yan Zhang; Oswald R Crasta; Bruno W Sobral; Carol A Gilchrist; William A Petri
Journal:  Int J Parasitol       Date:  2010-01-18       Impact factor: 3.981

Review 9.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

10.  New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres.

Authors:  Rebecca Robinson; James P Bertram; Jill L Reiter; Erin B Lavik
Journal:  J Microencapsul       Date:  2010-05       Impact factor: 3.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.